SwePub
Sök i LIBRIS databas

  Extended search

L773:1935 5548 OR L773:0149 5992
 

Search: L773:1935 5548 OR L773:0149 5992 > (2000-2004) > Beneficial effects ...

  • Alvarsson, MKarolinska Institutet (author)

Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients

  • Article/chapterEnglish2003

Publisher, publication year, extent ...

  • American Diabetes Association,2003
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-25458
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-25458URI
  • https://doi.org/10.2337/diacare.26.8.2231DOI
  • https://lup.lub.lu.se/record/116971URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:1956174URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • OBJECTIVE - To evaluate whether treatment with insulin in recently diagnosed type 2 diabetes is advantageous compared with glibenclamide treatment. RESEARCH DESIGN AND METHODS - ▀-Cell function, glycemic control, and quality of life were monitored over 2 years in 39 patients with islet cell antibody-negative type 2 diabetes diagnosed 0-2 years before inclusion in a Swedish multicenter randomized clinical trial. Patients were randomized to either two daily injections of premixed 30% soluble and 70% NPH insulin or glibenclamide (3.5-10.5 mg daily). C-peptide-glucagon tests were performed yearly in duplicate after 2-3 days of temporary withdrawal of treatment. RESULTS - After 1 year the glucagon-stimulated C-peptide response was increased in the insulin-treated group by 0.14 ▒ 0.08 nmol/l, whereas it was decreased by 0.12 ▒ 0.08 nmol/l in the glibenclamide group, P < 0.02 for difference between groups. After 2 years, fasting insulin levels were higher after treatment withdrawal in the insulin-treated versus the glibenclamide-treated group (P = 0.02). HbA1c levels decreased significantly during the first year in both groups, however, at the end of the second year, HbA1c had deteriorated in the glibenclamide group (P < 0.01), but not in the insulin-treated group. The difference in evolution of HbA1c during the second year was significant between groups, P < 0.02 A questionnaire indicated no difference in well-being related to treatment. CONCLUSIONS - Early insulin versus glibenclamide treatment in type 2 diabetes temporarily prolongs endogenous insulin secretion and promotes better metabolic control.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Sundkvist, GöranLund University,Lunds universitet,Institutionen för kliniska vetenskaper, Malmö,Medicinska fakulteten,Department of Clinical Sciences, Malmö,Faculty of Medicine(Swepub:lu)endo-gsu (author)
  • Lager, I (author)
  • Henricsson, M (author)
  • Berntorp, KerstinLund University,Lunds universitet,Genomik, diabetes och endokrinologi,Forskargrupper vid Lunds universitet,Genomics, Diabetes and Endocrinology,Lund University Research Groups(Swepub:lu)endo-kbe (author)
  • Fernqvist-Forbes, E (author)
  • Steen, L (author)
  • Westermark, Gunilla,1958-Linköpings universitet,Hälsouniversitetet,Cellbiologi(Swepub:liu)gunwe13 (author)
  • Westermark, P (author)
  • Orn, T (author)
  • Grill, Valdemar (author)
  • Karolinska InstitutetInstitutionen för kliniska vetenskaper, Malmö (creator_code:org_t)

Related titles

  • In:Diabetes Care: American Diabetes Association26:8, s. 2231-22370149-59921935-5548

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view